These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 20645917)

  • 1. 11C-verapamil to assess P-gp function in human brain during aging, depression and neurodegenerative disease.
    Bartels AL; de Klerk OL; Kortekaas R; de Vries JJ; Leenders KL
    Curr Top Med Chem; 2010; 10(17):1775-84. PubMed ID: 20645917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.
    Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Stundner G; Karch R; Brauner R; Meier M; Ding X; Müller M; Löscher W; Langer O
    Eur J Nucl Med Mol Imaging; 2010 May; 37(5):942-53. PubMed ID: 20016890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood-brain barrier P-glycoprotein function in neurodegenerative disease.
    Bartels AL
    Curr Pharm Des; 2011; 17(26):2771-7. PubMed ID: 21831040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using PET studies of P-gp function to elucidate mechanisms underlying the disposition of drugs.
    Syvänen S; Hammarlund-Udenaes M
    Curr Top Med Chem; 2010; 10(17):1799-809. PubMed ID: 20645912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET.
    Bankstahl JP; Kuntner C; Abrahim A; Karch R; Stanek J; Wanek T; Wadsak W; Kletter K; Müller M; Löscher W; Langer O
    J Nucl Med; 2008 Aug; 49(8):1328-35. PubMed ID: 18632828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET.
    Wagner CC; Bauer M; Karch R; Feurstein T; Kopp S; Chiba P; Kletter K; Löscher W; Müller M; Zeitlinger M; Langer O
    J Nucl Med; 2009 Dec; 50(12):1954-61. PubMed ID: 19910428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (R)-[11C]verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus.
    Syvänen S; Luurtsema G; Molthoff CF; Windhorst AD; Huisman MC; Lammertsma AA; Voskuyl RA; de Lange EC
    BMC Med Imaging; 2011 Jan; 11():1. PubMed ID: 21199574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography.
    Toornvliet R; van Berckel BN; Luurtsema G; Lubberink M; Geldof AA; Bosch TM; Oerlemans R; Lammertsma AA; Franssen EJ
    Clin Pharmacol Ther; 2006 Jun; 79(6):540-8. PubMed ID: 16765142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans.
    Muzi M; Mankoff DA; Link JM; Shoner S; Collier AC; Sasongko L; Unadkat JD
    J Nucl Med; 2009 Aug; 50(8):1267-75. PubMed ID: 19617341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic Modeling of (
    García-Varela L; García DV; Kakiuchi T; Ohba H; Nishiyama S; Tago T; Elsinga PH; Tsukada H; Colabufo NA; Dierckx RAJO; van Waarde A; Toyohara J; Boellaard R; Luurtsema G
    Mol Pharm; 2021 Jan; 18(1):416-428. PubMed ID: 33315404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation.
    Luurtsema G; Molthoff CF; Windhorst AD; Smit JW; Keizer H; Boellaard R; Lammertsma AA; Franssen EJ
    Nucl Med Biol; 2003 Oct; 30(7):747-51. PubMed ID: 14499333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in PET imaging of P-glycoprotein function at the blood-brain barrier.
    Syvänen S; Eriksson J
    ACS Chem Neurosci; 2013 Feb; 4(2):225-37. PubMed ID: 23421673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling cyclosporine A inhibition of the distribution of a P-glycoprotein PET ligand, 11C-verapamil, into the maternal brain and fetal liver of the pregnant nonhuman primate: impact of tissue blood flow and site of inhibition.
    Ke AB; Eyal S; Chung FS; Link JM; Mankoff DA; Muzi M; Unadkat JD
    J Nucl Med; 2013 Mar; 54(3):437-46. PubMed ID: 23359659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [PET imaging to study the functional impact of P-glycoprotein in neuropharmacokinetics].
    Marie S; Tournier N
    Therapie; 2020; 75(6):623-632. PubMed ID: 32200996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET.
    Bart J; Willemsen AT; Groen HJ; van der Graaf WT; Wegman TD; Vaalburg W; de Vries EG; Hendrikse NH
    Neuroimage; 2003 Nov; 20(3):1775-82. PubMed ID: 14642487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic Models for Measuring P-glycoprotein Function at the Blood-Brain Barrier with Positron Emission Tomography.
    Lubberink M
    Curr Pharm Des; 2016; 22(38):5786-5792. PubMed ID: 27494063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Locally increased P-glycoprotein function in major depression: a PET study with [11C]verapamil as a probe for P-glycoprotein function in the blood-brain barrier.
    de Klerk OL; Willemsen AT; Roosink M; Bartels AL; Hendrikse NH; Bosker FJ; den Boer JA
    Int J Neuropsychopharmacol; 2009 Aug; 12(7):895-904. PubMed ID: 19224656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET.
    Bauer M; Karch R; Neumann F; Abrahim A; Wagner CC; Kletter K; Müller M; Zeitlinger M; Langer O
    Eur J Clin Pharmacol; 2009 Sep; 65(9):941-6. PubMed ID: 19655132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of P-glycoprotein function at the human blood-brain barrier using [
    Mossel P; Arif WM; De Souza GS; Varela LG; van der Weijden CWJ; Boersma HH; Willemsen ATM; Boellaard R; Elsinga PH; Borra RJH; Dierckx RAJO; Lammertsma AA; Bartels AL; Luurtsema G
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3917-3927. PubMed ID: 37552369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA.
    Bartels AL; Willemsen AT; Kortekaas R; de Jong BM; de Vries R; de Klerk O; van Oostrom JC; Portman A; Leenders KL
    J Neural Transm (Vienna); 2008 Jul; 115(7):1001-9. PubMed ID: 18265929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.